TScan Therapeutics (TCRX.US) issued 30 million U.S. dollars of pre-financing warrants.

Biotechnology company TScan Therapeutics (TCRX.US) announced on Thursday that it will sell approximately $30 million in pre-financing warrants, which can be used to purchase a total of up to 7.5 million shares with voting rights at a price of $4.00 per share. As of the time of writing, the company's stock was up 22.68% in pre-market trading, at $3.57. TCRX has entered into a securities purchase agreement with Lynx1 Capital Management and Lynx1 Consulting's investment fund. Each pre-financing warrant can be exercised to purchase one share with voting rights of common stock at an exercise price of $0.0001 per share. The financing is expected to be completed around December 27th.